Optiscan Launches InSpecta Device for Veterinary Medicine
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has announced the launch of its InSpecta device for veterinary medicine in the U.S. market, marking a significant milestone for the company. The InSpecta device, designed for veterinary practices, aims to enhance clinical decision-making and workflow efficiency by providing real-time cellular imaging. This launch follows the successful submission of its regulatory dossier to the FDA, allowing Optiscan to commence commercial sales activities in the veterinary sector. The device will be showcased at the American Veterinary Medical Association Convention, providing exposure to key industry stakeholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Optiscan Receives $1.69m R&D Tax Refund
- Optiscan Submits InSpecta FDA Dossier
- Appendix 4D
Later from Optiscan Imaging
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Signs New Research Agreement for Breast Study
- Preliminary Final Report
- Optiscan Initiates Head and Neck Cancer Study in the US
- Significant Milestone Reached in ACL Digital Pathology Study
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging